Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · third_quarter · Q3
General issues related to international intellectual property; provision ISI committee report language, amendments and march-in rights within S. 1519 National Defense Authorization Act for Fiscal Year 2018 and provision ISI committee report language, amendments and march-in rights within H.R. 2810 National Defense Authorization Act for Fiscal Year 201.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Source: Senate LDA
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Affordable and Safe Prescription Drug Importation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Safe and Affordable Drugs from Canada Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Drug Diversion and Counterfeit Crackdown Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to patent reform; H.R. 2376 Drug Diversion and Counterfeit Crackdown Act of 2017 to increase penalties for drug diversion.
FDA Reauthorization Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
FDA Reauthorization Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
National Defense Authorization Act for Fiscal Year 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to international intellectual property; provision ISI committee report language, amendments and march-in rights within S. 1519 National Defense Authorization Act for Fiscal Year 2018 and provision ISI committee report language, amendments and march-in rights within H.R. 2810 National Defense Authorization Act for Fiscal Year 201.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Lower Drug Costs through Competition Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Protecting Seniors Access to Medicare Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
National Defense Authorization Act for Fiscal Year 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to international intellectual property; provision ISI committee report language, amendments and march-in rights within S. 1519 National Defense Authorization Act for Fiscal Year 2018 and provision ISI committee report language, amendments and march-in rights within H.R. 2810 National Defense Authorization Act for Fiscal Year 201.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Protecting Medicare from Executive Action Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Protecting Seniors' Access to Medicare Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Safe and Affordable Drugs from Canada Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · second_quarter · Q2
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
General issues related to patent reform; H.R. 2376 Drug Diversion and Counterfeit Crackdown Act of 2017 to increase penalties for drug diversion.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
General issues related to international intellectual property.
General issues related to border adjustability tax; issues related to interest deductibility; issues related to Orphan Drug Tax Credit.
General issues related to Buy American/American First; issues related to international drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE